Molecular Evidence (rationale) for VEGF targeted therapy in iMCD patients:


  • "VEGF is frequently elevated in iMCD. VEGF, which promotes cell survival, angiogenesis, and vascular permeability, is often elevated in parallel with iMCD symptoms" (blood 2014)


Case Reports of anti-VEGF therapy for iMCD patients:


Sirolimus (Rapamycin) is an mTOR inhibitor that blocks VEGF expression by inhibiting mTOR.

  • To learn more about sirolimus as treatment for iMCD, please click here. 
     

Clinical Trials targeting VEGF in iMCD: 


No clinical trials targeting VEGF in iMCD patients have been conducted.